Previous 10 | Next 10 |
Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs In calendar 2022, the company achieved a number of milestones in various areas,...
Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs, has, since inception, been committed to addressing severe unmet patient needs. Hypertension has been one of its main focus areas. “Lex...
Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research program The program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drug The...
Approximately 55 million people worldwide have dementia, which is expected to grow to 78 million by 2030 The dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029 Clinical studies have ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its patented DehydraTECH-CBD(TM) has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). According to the up...
KELOWNA, BC / ACCESSWIRE / November 29, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its patented DehydraTECH-CBD™ has demonstrated performance enhancements compared to one of the...
--News Direct-- Kelowna, British Columbia – TheNewswire - November 29, 2022 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that its patented Dehydra...
Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, was featured in an interview produced by PCG Digital Holdings LLC and published on NewMediaWire . John Docherty, Lexaria’s president and head of research, discussed the company’s efforts...
In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed C...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Website:
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...